Nivolumab for Carcinoma, Non-Small-Cell Lung
This study is evaluating whether a new drug called nivolumab can help treat lung cancer.
See full descriptionAbout the trial for Carcinoma, Non-Small-Cell Lung
Treatment Groups
This trial involves 3 different treatments. Nivolumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Carcinoma, Non-Small-Cell Lung or the other condition listed above. There are 7 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Nivolumab will improve 1 primary outcome and 4 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of Up to 47 months.
Patient Q & A Section
What are the signs of carcinoma, non-small-cell lung?
Given the increasing incidence of lung cancer, with a declining average age of diagnosis, this article provides an overview of the available clinical literature and the signs of carcinoma, non-small-cell lung. This overview is intended to help in the identification of new lung cancers and in the early exclusion of more benign lung lesions.
How many people get carcinoma, non-small-cell lung a year in the United States?
around 683,000 people will have carcinoma, non-small-cell lung each year in the Unites States. Overall, a quarter of cancers in women with an underlying lung disease are due to this type of cancer.
Can carcinoma, non-small-cell lung be cured?
The current results show a lack of effective treatment strategies for NSCLC. The lack of cure, combined with the long duration of most NSCLC clinical trials (range of 10-40 weeks) and the limited number of patients included, make current results difficult to apply to a clinical perspective or to patients with NSCLC. Further, and larger, multicenter trials need to be carried out.
What is carcinoma, non-small-cell lung?
Cancer, non-small-cell lung is the second most common invasive cancer, responsible for roughly 7.8% of all cancer cases annually in the U.S and is the second leading cause of cancer death (after breast cancer) and, along with lung cancer, is the largest contributor to cancer-related mortality in the U.S. Cancer, non-small-cell lung can cause a wide spectrum of signs and symptoms, including shortness of breath, pain, and weight loss. People with cancer, non-small cell lung can have an impaired quality of life due to their disease, which leads to a decrease in their overall health and a decreased ability to care for themselves and their family.
What are common treatments for carcinoma, non-small-cell lung?
The 5-year overall survival for patients with metastatic carcinoma, non-small-cell lung is about 17%; and the survival from metastatic carcinoma, non-small-cell lung is about 14%. Very common treatments for metastatic carcinoma, non-small-cell lung include surgery, radiotherapy, and chemotherapy.
What causes carcinoma, non-small-cell lung?
The causes of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) can be broken down into hereditary factors, environmental and lifestyle factors, and, lastly, cancer-related factors. It is important to acknowledge that the causes of lung cancer include many genetic and environmental factors that are not clearly identified.
How serious can carcinoma, non-small-cell lung be?
Lung carcinoma is the second most common cancer in the US and is responsible for 11 percent of cancer deaths, with an additional 11 percent in the 20-to-40-year-old age group. Most patients survive after two years and almost to their death: the probability of survival is approximately 0.3% per year. However, the chances of survival in the first year of diagnosis are over 90%. The overall five-year survival rate of lung cancer is about 43 to 70%, with the most common causes of disease mortality being pleural effusion, bone cancer, consolidation, and infection (mostly due to bacterial pneumonia or tuberculosis).
Has nivolumab proven to be more effective than a placebo?
In the first 12 weeks in the RECIST 1.1 phase I/II trial, treatment with NIV-V10 was generally well tolerated with few infusion- and dose-limiting events. More durable response rates will be needed to define the clinical significance of this study.
What does nivolumab usually treat?
Nivolumab often inhibits [cancer cells with mutated EGFR gene (which has been proven to be a marker of aggressive cancers)] but can also restrain tumour growth in some of the less aggressive cancers. A single cycle of nivolumab typically leads to tumour regression in certain cancers; its use at a higher dose and at a later time points is, however, warranted to achieve durable responses, which will be most likely to affect the overall survival.
What are the chances of developing carcinoma, non-small-cell lung?
According to the SEER database, a 6-fold higher overall risk (OR =6.0) and a 7-fold increased risk (OR =7.2) of developing carcinoma, non-small cell lung, exists among those with previous cases of these types of cancers. In the following table, a greater risk of developing lung cancer is indicated by a greater OR.
What are the common side effects of nivolumab?
In patients treated with nivolumab, common adverse events included fatigue (63.4% of patients) and gastrointestinal events (31.0% of patients), more so than in patients treated with systemic therapy alone (29.5% vs 28%). There were no clinical differences in side effects between nivolumab-treated patients and those receiving systemic therapy with chemotherapy and/or radiation therapy. Although fatigue was frequent, more than half of nivolumab-treated patients reported an improvement in fatigue compared with systemic therapy alone. Further studies are necessary to better understand this adverse effect and develop patient treatment strategies.
What is the average age someone gets carcinoma, non-small-cell lung?
Nearly half (49.0) of lung cancers reported in the United States are diagnosed in people aged 65 or older. The survival rate for lung cancer is lower for this population. In an era of universal healthcare coverage, advances in prevention and early detection may improve survival rates for seniors with lung cancer.